In a recent publication, Zeng et al. showed an in vitro study and immunofluorescent staining highlighting CCL18 signaling and NFKb-signaling by tumor-associated macrophages (TAMs) as an activator of stromal cells associated with poor prognosis in breast cancer patients. Here, NFKB1 is linked to breast cancer.